Solutions for CAR-T Antibody Development
We provide integrated R&D service of CAR-T antibodies preclinical candidate (PCC) R&D service covers six major modules, including material preparation, antibody discovery, in vitro efficacy screening, antibody engineering, in vivo efficacy evaluation and quality analysis. The close connections and cooperation between various modules help customers to quickly complete the research and development of the antibody for CAR-T therapy.
Service Highlights
1. Fast antibody discovery
l Various types of differentiated antibody libraries are available for high-quality, fast-speed, and cost-efficient PCC R&D.
2. Integrated R&D platforms
l A series of featured technology platforms make the R&D of CAR-T antibodys simple and efficient. With closely connected modules and preparation, the integrated R&D platforms enable delivery of the PCC antibodies for CAR-T within 12 months.
3. Enriched R&D experience
l We have developed several candidates for CAR-T and accumulated extensive R&D experience.
热门文章
Cre-ERT2在无Tamoxifen诱导的情况下，在细胞质内处于无活性状态；当Tamoxifen诱导后，Tamoxifen的代谢产物4-OHT（雌激素类似物）与ERT结合，可使Cre-ERT2进核发挥Cre重组酶活性。
查看你一定听说过Cre-lox重组系统，无论你是否直接进行过基因操作。由于Cre-lox系统具有操作简单、重组率高的优点，如今已经成为体内外遗传操作的强有力工具。利用Cre-lox系统，可以在特定细胞、组织或整个生物体，甚至在特定时间点敲除或表达某个基因，实现对特定基因的时空特异性操作，这对基因功能的研究和人类疾病动物模型的建立都具有深刻影响。
查看
